Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Oct 20, 2017
Clinical News

uniQure maps plan for hemophilia B gene therapy

BioCentury | Oct 19, 2017
Clinical News

uniQure maps plan for hemophilia B gene therapy

BioCentury | Aug 3, 2017
Emerging Company Profile

Tunable cell therapies

Sigilon's allogeneic cell therapy implants offer long-term but flexible dosing
BioCentury | Apr 15, 2017
Product Development

Outside factors

How new hemophilia products could usher in personalized treatment strategies
BioCentury | Feb 22, 2017
Distillery Therapeutics

Hematology

BioCentury | Feb 11, 2017
Strategy

Building Bioverativ

How Biogen spinout Bioverativ plans to survive as stand-alone company
BioCentury | Feb 3, 2017
Clinical News

AMT-060 regulatory update

BioCentury | Nov 18, 2016
Company News

uniQure restructuring news

BioCentury | Nov 15, 2016
Company News

uniQure paring down gene therapy portfolio

Items per page:
1 - 10 of 37